alendronate has been researched along with Disease Models, Animal in 181 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (7.73) | 18.2507 |
| 2000's | 58 (32.04) | 29.6817 |
| 2010's | 93 (51.38) | 24.3611 |
| 2020's | 16 (8.84) | 2.80 |
| Authors | Studies |
|---|---|
| Carter, E; Jepsen, K; Oswald, J; Pleshko, N; Querido, W; Raggio, C; Shanas, N | 1 |
| Feng, P; Shu, S; Zhao, F | 1 |
| Cronstein, BN; Flatow, JS; Gao, ZG; Haraczy, AJ; Jacobson, KA; Larrañaga-Vera, A; Leucht, P; Mediero, A; Rao, H; Sussman, SM; Toti, KS; Warnick, E | 1 |
| Ahmida, A; Chen, PJ; Kalajzic, Z; Mehta, S; Wang, K; Yadav, S; Zhichao, F | 1 |
| Cai, H; Fu, L; Li, G; Liu, C; Liu, Q; Liu, Y; Pan, Y; Wu, J; Yang, Q; Yu, Y; Zhong, J | 1 |
| Apostolova, D; Batsalova, T; Belenska-Todorova, L; Dzhambazov, B; Georgieva, E; Ivanovska, N; Lambova, SN; Moten, D; Stoyanova, S | 1 |
| Beninatto, R; Galesso, D; Galuppini, F; Giraudo, C; Guarise, C; Guzzardo, V; Lazzarin, V; Luisetto, R; Masiero, S; Pavan, M; Pennelli, G; Scanu, A | 1 |
| Ha, TTM; Lai, TT; Nguyen, HVM; Pham, CV; Pham, TT; Phuong, TT; To, TT; Tran, LD; Trinh, DC; Winkler, C | 1 |
| Chai, Y; Chen, PS; Chen, Z; Cheng, C; Cui, Z; Hu, Y; Li, K; Su, J; Wang, Y; Wu, H; Wu, X; Xu, T; Yao, Z; Yu, B; Zhang, H; Zhang, X | 1 |
| Bi, J; Liu, S; Qu, D; Song, Q; Sun, X; Yu, M; Zhang, Y | 1 |
| Huang, G; Li, B; Ma, Z; Qin, S | 1 |
| Alaeddini, M; Dehpour, AR; Doustimotlagh, AH; Eskandarynasab, M; Etemad-Moghadam, S; Goudarzi, R; Partoazar, A; Takzaree, N | 1 |
| Ci, T; Ke, X; Luo, Y; Wu, H; Xu, D | 1 |
| Chen, R; He, H; Ma, C; Shi, C; Sun, B; Wu, H; Zhang, Y | 1 |
| Bakker, NEC; Geven, EJW; Gossen, JA; Link, DP; van de Ven, CJJM | 1 |
| Cai, M; Chen, Y; Li, Y; Min, W; Wang, C; Wang, J; Yan, L; Zhang, R; Zhu, H | 1 |
| Faverani, LP; Freire, AR; Gruber, R; Hassumi, JS; Luvizuto, ER; Momesso, GAC; Okamoto, R; Polo, TOB; Prado, FB; Ramalho-Ferreira, G; Rossi, AC | 1 |
| Gao, GC; Liu, CT; Yuan, XJ | 1 |
| Abdollahifar, M; Ahadi, R; Bayat, M; Ghorishi, SK; Jalalifirouzkouhi, A; Mostafavinia, A | 1 |
| Ahrens, BJ; Bading, JR; Chea, J; Ciminera, AK; Colcher, DM; Li, L; Miller, MM; Poku, E; Shively, JE; Weist, MR | 1 |
| Guo, D; He, H; Hou, T; Kolba, N; Liu, Y | 1 |
| Fu, G; Jiang, W; Lai, D; Lv, X; Rong, X; Xu, S; Yang, Y | 1 |
| Harada, A; Hashimoto, N; Kawada, S | 1 |
| Amling, M; Cornils, K; Fehse, B; Hermans-Borgmeyer, I; Jeschke, A; Oheim, R; Rolvien, T; Schinke, T; Triviai, I; Vollersen, N; Yorgan, TA | 1 |
| Huang, J; Jiang, X; Qiu, T; Ren, H; Shen, G; Tang, J; Yang, Z; Yao, Z; Yu, X; Zhang, Z; Zhao, W | 1 |
| Adebayo, OO; Goldring, MB; Goldring, SR; Ko, FC; van der Meulen, MCH; Wan, PT; Wright, TM | 1 |
| Aktas, A; Barıs, E; Çelik, HH; Özer, T; Vatansever, A | 1 |
| Camacho-Alonso, F; Davia-Peña, RS; Martínez-Beneyto, Y; Merino, JJ; Tudela-Mulero, MR; Vilaplana-Vivo, C | 1 |
| Huang, Y; Leng, B; Li, X; Lin, J; Mei, X; Pan, Y; Qiu, J; Su, Y; Xing, C; Xu, J; Xue, Y; Zhang, W | 1 |
| Hauser, M; Hofstetter, W; Keller, I; Siegrist, M | 1 |
| Elfiky, AA; Sayed, AA | 1 |
| Cho, DC; Gupta, R; Han, I; Kim, CH; Kim, KT; Kwon, JT; Lee, YS; Park, EK; Seo, YJ; Seu, SY; Sung, JK | 1 |
| Chen, X; Geng, T; Guo, H; Jin, Q; Sun, S; Yu, H; Zhang, S; Zheng, M | 1 |
| Cao, X; Ding, Q; Ding, S; Qin, Y; Tang, S; Zhen, G | 1 |
| Huo, Q; Li, Y; Liu, Y; Niu, Y; Shi, H; Xu, M; Yang, F; Zhu, J | 1 |
| Iino, T; Kato, S; Miyamura, G; Naito, Y; Nakagawa, T; Sudo, A; Wakabayashi, H | 1 |
| Kato, S; Miyamura, G; Nagao, N; Naito, Y; Sudo, A; Wakabayashi, H | 1 |
| Beattie, JR; Bell, SEJ; Caraher, MC; Cummins, NM; Idris, AI; O'Driscoll, O; Rahimnejad Yazdi, A; Ralston, SH; Sophocleous, A; Towler, M | 1 |
| Hu, X; Qi, B; Wang, Z; Xiao, W; Yu, A; Zhang, D; Zhao, Y | 1 |
| Akhtar, M; Ismail, MV; Kaundal, M; Najmi, AK; Parwin, A | 1 |
| Carney, TJ; Ethiraj, LP; Roehl, HH; Sánchez, LM; Tomecka, MJ | 1 |
| Dambacher, MA; Dukas, L; Ringe, JD; Von Schacht, E | 1 |
| Dai, KR; Fu, LJ; Hao, YQ; Tang, TT | 1 |
| Abtahi, J; Agholme, F; Aspenberg, P | 1 |
| Hu, QF; Luo, Y; Song, HP; Su, YL; Wang, WY; Zhang, L; Zhang, YZ | 1 |
| Barak, M; Bejar, J; Norman, D; Orion, E; Peled, E | 1 |
| Beyea, SD; Bezuhly, M; Boyd, D; Hong, P | 1 |
| Berti-Couto, SA; Cherubini, K; Figueiredo, MA; Iglesias, JE; Salum, FG; Vasconcelos, AC | 1 |
| Bahremand, A; Dehpour, AR; Derakhshanian, H; Djalali, M; Djazayery, A; Ghadbeigi, S; Nourijelyani, K; Pishva, H; Saedisomeolia, A | 1 |
| Begun, DL; Caird, MS; Goldstein, SA; Kozloff, KM; Marini, JC; McElderry, JD; Meganck, JA; Morris, MD; Swick, A | 1 |
| Gupta, S; Khandelwal, M; Manglani, K; Surolia, A; Vijayan, V | 1 |
| Almalki, AL; Elshal, MF; Hussein, HK; Khan, JA | 1 |
| Asplin, JR; Bushinsky, DA; Culbertson, CD; Frick, KK; Granja, I; Krieger, NS | 1 |
| Abe, Y; Amizuka, N; Chiba, H; Iba, K; Kanaya, K; Kawamata, T; Oda, K; Sasaki, K; Sasaki, M; Yamashita, T | 1 |
| Abo Hager, EA; Amin, G; El Shiekh, MA; Hazzaa, HH | 1 |
| Amugongo, SK; Dai, W; Dave, NK; Jia, J; Jiang, L; Lane, NE; Lay, YA; Li, CS; Olivera, D; Panganiban, B; Ritchie, RO; Walsh, D; Yao, W | 1 |
| Burwitz, BJ; Ericsen, AJ; Golomb, G; Hammond, KB; Legasse, AW; Ohme, MA; Planer, SL; Reed, JS; Richter, Y; Sacha, JB | 1 |
| Dorval Courchesne, NM; Hammond, PT; Hyder, MN; Nevins, M; Quadir, MA; Seeherman, HJ; Shah, NJ; Spector, M | 1 |
| Chen, SY; Chiang, SS; Kao, JP; Mau, JL; Mishchuk, DO; Slupsky, CM; Yang, CC; Yu, HT | 1 |
| Acerbo, AS; Judex, S; Kwaczala, AT; Miller, LM; Yang, L | 1 |
| Choi, DY; Huh, JE; Kang, JW; Kim, SJ; Lee, JD; Nam, DW; Park, DS | 1 |
| Ahmad, N; Gautam, J; Khedgikar, V; Kushwaha, P; Mishra, PR; Nagar, GK; Sangwan, NS; Singh, D; Trivedi, PK; Trivedi, R | 1 |
| Bae, J; Park, JW | 1 |
| Banfi, G; Congiu, T; Mariotti, M; Pasqualetti, S | 1 |
| Cankaya, D; Gunay, MC; Ozturk, AM; Tabak, Y | 1 |
| Boskey, AL; Carter, EM; Doty, S; Marino, J; Pleshko, N; Raggio, CL; Spevak, L | 1 |
| Chen, G; Grynpas, MD; Hu, S; Liu, CC; Willett, T; Young, RN | 1 |
| Habu, M; Kokuryo, S; Nishihara, T; Sakaguchi, O; Tanaka, J; Tominaga, K; Tsurushima, H; Yoshiga, D; Yoshioka, I | 1 |
| Li, F; Li, HQ; Mei, QB; Na, R; Ye, WL; Zhao, MG; Zhao, YP; Zhou, SY | 1 |
| Acar, N; Balkarli, H; Celik-Ozenci, C; Korkusuz, P; Ozbey, O; Soyuncu, Y; Ustunel, I | 1 |
| Baek, SY; Kim, HY; Lee, CH; Lee, MY; Park, YK; Singh, D; Yeo, SH | 1 |
| Andrade, CR; Conte, N; Esteves, JC; Marcantonio, E; Spolidorio, LC | 1 |
| Hamano, H; Hiratsuka, S; Iwasaki, N; Kameda, Y; Kanehira, Y; Kimura-Suda, H; Ota, M; Sato, D; Shimizu, T; Takahata, M | 1 |
| Guo, W; Huang, XH; Liang, RH; Su, L; Wang, CJ | 1 |
| Iino, T; Kato, S; Naito, Y; Nakagawa, T; Sudo, A; Wakabayashi, H | 1 |
| Chin, CM; Faig-Leite, H; Fernandes, RG; Nobre, MD | 1 |
| de Melo Ocarino, N; de Oliveira Pereira, RD; Diniz, JS; do Carmo Magalhães, F; Nicolau, RA; Serakides, R | 1 |
| Altavilla, D; Antoci, S; Armbruster, MA; Bitto, A; Burnett, BP; Di Stefano, V; Granese, R; Irrera, N; Levy, RM; Marini, H; Minutoli, L; Polito, F; Squadrito, F | 1 |
| Glimcher, MJ; Hofstaetter, JG; Wang, J; Yan, J | 1 |
| Danenberg, HD; Golomb, G; Haber, E; Koroukhov, N; Ron-El, R; Schachter, M | 1 |
| Brookler, K | 1 |
| Allen, MR; Burr, DB; Erickson, AM; Hazelwood, SJ; Martin, RB; Wang, X | 1 |
| Capaldi, ML; Castilho, LR; de Moraes, IG; Mori, GG; Nunes, DC; Poi, WR | 1 |
| Altavilla, D; Armbruster, MA; Bitto, A; Burnett, BP; Di Stefano, V; Irrera, N; Levy, RM; Marini, H; Minutoli, L; Polito, F; Squadrito, F | 1 |
| Bünger, C; Christensen, FB; Dalstra, M; Li, H; Lind, M; Xue, Q; Zou, X | 1 |
| Asuncion, F; Chiusaroli, R; Khatri, R; Kostenuik, P; Ohishi, M; Ominsky, M; Schipani, E; Thomas, C | 1 |
| Allen, MR; Burr, DB; Diab, T; Koivunemi, A; Koivunemi, M | 1 |
| Agholme, F; Aspenberg, P | 1 |
| Allen, MR; Burr, DB | 1 |
| Hoerster, AK; Kolios, L; Malcherek, MC; Rack, T; Sehmisch, S; Seidlova-Wuttke, D; Stuermer, EK; Stuermer, KM; Tezval, M; Wuttke, W | 1 |
| Chen, H; Chen, L; Chen, LW; Guo, XS; Qi, DS; Xu, HZ; Zhang, GY | 1 |
| Anastassopoulos, G; Christopoulou, G; Karamanos, N; Khaldi, L; Lyritis, G; Panagiotopoulos, E; Panteliou, S; Stavropoulou, A; Varakis, J | 1 |
| Chen, BL; Li, FB; Li, YQ; Liao, WM; Lu, W; Ning, CY; Xie, DH; Zheng, ZM | 1 |
| Joshi, A; Singh, S; Singh, V | 1 |
| Hong, BY; Im, S; Ko, YJ; Lee, JI; Lim, SH; Park, GY; Park, JH | 1 |
| Doschak, MR; Jones, MD; Li, G; Maksymowych, WP; Tran, CW; Zernicke, RF | 1 |
| Hu, Y; Peng, B; Wei, L; Xiong, H; Zhang, C | 1 |
| Cottrell, JA; Gundlapalli, R; Kapadia, R; O'Connor, JP; Schachter, D; Vales, FM; Wadsworth, S | 1 |
| Fu, Q; Hao, XJ; Hu, SM; Li, J; Wang, Q; Wu, ZR; Yang, JJ; Zhu, B | 1 |
| Bo, W; Hai, T; Jindong, Z; Junchao, G; Li, B; Qiang, WB | 1 |
| Afergan, E; Ben-David, M; Epstein, H; Golomb, G; Gutman, D; Haber, E; Koroukhov, N; Schachter, M | 1 |
| Azambuja, AA; Campos, MM; Cherubini, K; Maahs, MP; Salum, FG | 1 |
| Carta, L; Cook, JR; Dietz, HC; Lee-Arteaga, S; Nistala, H; Ramirez, F; Rifkin, AN; Rifkin, DB; Siciliano, G; Smaldone, S | 1 |
| Coelho, PG; Giro, G; Jorgetti, V; Marcantonio, E; Orrico, SR; Pereira, RM | 1 |
| Boden, SD; Kawakami, M; Minamide, A; Nakao, S; Yoshida, M | 1 |
| Hu, H; Song, H; Tian, F; Zhang, L; Zhang, Y | 1 |
| Chen, T; Hu, HJ; Lu, TL; Zhao, W | 1 |
| Ducy, P; Guo, XE; Inose, H; Karsenty, G; Yadav, VK; Zhou, B | 1 |
| Asuncion, FJ; Barrero, M; Dwyer, D; Grisanti, M; Ke, HZ; Kostenuik, PJ; Li, X; Niu, QT; Ominsky, MS; Paszty, C; Simonet, WS; Stolina, M; Warmington, KS | 1 |
| Bargman, R; Boskey, AL; DiCarlo, E; Pleshko, N; Posham, R; Raggio, C | 1 |
| Ho, HY; Ko, YJ; Lin, WC; Wu, JB | 1 |
| Cao, PC; Lei, W; Liu, D; Liu, N; Qi, W; Shi, L; Wu, ZX; Yan, YB; Zhang, Y | 1 |
| Abtahi, J; Agholme, F; Aspenberg, P; Sandberg, O | 1 |
| Cusick, T; Duong, L; Fisher, JE; Glantschnig, H; Karanam, B; Scott, K; Tijerina, M; Wei, N; Zhao, JZ | 1 |
| Hayashi, R; Hirai, Y; Hitomi, K; Kamiyama, F; Katsumi, H; Kusamori, K; Liu, S; Quan, YS; Sakane, T; Tanaka, Y; Yamamoto, A | 1 |
| Duong, LT; Hayami, T; Pickarski, M; Wesolowski, GA; Zhuo, Y | 1 |
| Alcaraz, MJ; Caeiro, JR; Ferrándiz, ML; Guede, D; Ibáñez, L; Maicas, N; Motterlini, R | 1 |
| Cao, X; Niu, S; Zhang, Y; Zhen, P; Zhu, J; Zhu, Q | 1 |
| Eren, K; Ozdemir, H; Ozer, H; Toker, H | 1 |
| Axelman, E; Davis, M; Nadir, Y; Norman, D; Peled, E | 1 |
| He, D; Luo, Y; Wei, Q; Yin, M | 1 |
| Jahr, H; Kops, N; Schaden, W; van der Jagt, OP; Verhaar, JA; Waarsing, JH; Weinans, H | 1 |
| Andrade, CR; Conte Neto, N; Guimarães, M; Marcantonio, E; S Bastos, A; Spolidorio, LC | 1 |
| Boskey, AL; Camacho, NP; Hossack, MD; Jain, S; McCarthy, EA; Miller, EA; Raggio, CL | 1 |
| Camacho, NP; Carroll, P; Raggio, CL | 1 |
| Bahar, H; Binderman, I; Kollerman, R; Yaffe, A | 1 |
| Evans, KD; Lau, ST; Martin, RB; Oberbauer, AM | 1 |
| Aspenberg, P; Astrand, J; Skoglund, B; Skripitz, R | 1 |
| Bostanci, H; Günhan, O; Kaynak, D; Meffert, R; Ozkaya, OG | 1 |
| Danenberg, HD; Edelman, ER; Epstein, H; Gao, J; Golomb, G; Groothuis, A; Seifert, P; Swaminathan, RV | 1 |
| Aspenberg, P; Astrand, J | 3 |
| Bone, A; Destefano, J; Duong, LT; Hayami, T; McLane, J; Pickarski, M; Rodan, GA; Wesolowski, GA | 1 |
| Gámez, R; Más, R; Mendoza, N; Mendoza, S; Noa, M | 1 |
| Bünger, C; Bünger, M; Christensen, FB; Egund, N; Li, H; Lind, M; Xue, Q; Zou, X | 2 |
| Cammisa, FP; Huang, RC; Khan, SN; Lane, JM; Myers, ER; Sama, AA; Sandhu, HS | 1 |
| Azuma, Y; Miyaji, T; Nakase, T; Shimizu, N; Uchiyama, Y; Yoshikawa, H | 1 |
| Baldini, T; Boskey, AL; Camacho, NP; Fratzl, P; Klaushofer, K; Misof, BM; Raggio, CL; Root, L; Roschger, P; Zraick, V | 1 |
| Abe, E; Fallon, JT; Fisher, EA; Shimshi, M; Zaidi, M | 1 |
| Huang, J; Huo, JS; Li, WX; Liu, CX; Liu, ZP; Sun, J; Yu, B | 1 |
| Badell, IR; Boulukos, KE; Boyce, BF; Schwarz, EM; Xing, L; Yao, Z; Zhang, Q | 1 |
| Goto, S; Kameyama, Y; Kawai, T; Kimura, M; Maeda, H; Miyazawa, K; Tabuchi, M | 1 |
| Andresen, CJ; Bagi, CM; Berryman, E; Hanson, N; Moalli, M; Olson, E; Shen, V; Volberg, M | 1 |
| Aktekin, CN; Altay, M; Erdemli, E; Karahuseyinoglu, S; Korkusuz, F; Ozturk, AM; Tabak, AY | 1 |
| Marcantonio, E; Marcantonio, RA; Nassar, CA; Nassar, PO; Rossa, C; Spolidorio, DM; Spolidorio, LC | 1 |
| Honda, S; Imai, H; Nagai, T; Negi, A | 1 |
| Hashimoto, J; Miki, H; Nishii, T; Sugano, N; Yoshikawa, H | 1 |
| Danielsen, CC; Ding, M; Hvid, I | 1 |
| Higaki, H; Iwamoto, Y; Mawatari, T; Miura, H | 1 |
| Abu-Ali, S; Fotovati, A; Hayashi, K; Naito, M; Nakamura, Y | 1 |
| Iwamoto, J; K Yeh, J; Matsumoto, H; Sato, Y; Takeda, T | 1 |
| De Leo, L; Decorti, G; Marcuzzi, A; Not, T; Pontillo, A; Tommasini, A; Ventura, A | 1 |
| Awad, HA; Bechtold, CD; Bukata, SV; Hock, C; Ito, H; Nakamura, T; O'Keefe, RJ; Proulx, ST; Schwarz, EM; Tsutsumi, R | 1 |
| Borke, JL; Hou, X; Ruan, WH; Sharawy, MM; Viera-Negrón, YE; Winger, JN | 1 |
| Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M | 1 |
| Jacks, TM; Jeffcoat, MK; Reddy, MS; Smith, CA; Weatherford, TW; West, BD | 1 |
| Balena, R; Gentile, M; Markatos, A; Masarachia, P; Rodan, GA; Seedor, JG; Yamamoto, M | 1 |
| Balena, R; Rodan, GA; Seedor, JG | 1 |
| Antic, VN; Fleisch, H; Mühlbauer, RC | 1 |
| Black, EC; Bryant, HU; Chandrasekhar, S; Frolik, CA; Magee, DE | 1 |
| Löwik, CW; Papapoulos, SE; van Beek, ER | 1 |
| Bowman, AR; Epstein, S; Jee, WS; Ma, Y; Sass, DA; Yuan, Z | 1 |
| Rodan, GA | 1 |
| Boivin, G; Meunier, PJ | 1 |
| Asplin, J; Bushinsky, DA; Krieger, NS; Neumann, KJ | 1 |
| Adut, M; Binderman, I; Yaffe, A | 1 |
| Binderman, I; Breuer, E; Golomb, G; Yaffe, A | 1 |
| Benz, EB; Goater, JJ; Lu, AP; Mollano, AV; Okeefe, RJ; Puzas, JE; Rosier, RN; Schwarz, EM | 1 |
| da Paz, LH; de Falco, V; dos Reis, LM; Jorgetti, V; Pereira, RM; Teng, NC | 1 |
| Bryson, EC; Caplan, D; Levin, L; Trope, M | 1 |
| Boskey, AL; Camacho, NP; Doty, SB; Ilg, WA; Raggio, CL; Root, L; Toledano, TR; Zraick, V | 1 |
| Baitner, A; Di Cesare, PE; Frenkel, SR; Hawkins, M; Jaffe, WL; Jazrawi, L; Maurer, S; Sala, D; Valle, CD; Wright, K | 1 |
| Chen, LT; Huang, YC; Lin, FH; Sun, JS; Tsuang, YH | 1 |
| Barmada, R; Gonzalez, MH; Sladek, E; Thadani, PJ; Waxman, B | 1 |
| Wang, X; Yang, Z; Yu, S | 1 |
| Allen, MJ; Bostrom, MP; Millett, PJ | 1 |
| Caputo, JM; Price, PA; Williamson, MK | 1 |
| Clair, J; Davidson, J; Fioravanti, C; Frankenfield, D; Jackson, R; Klein, H; Quartuccio, H; Seedor, JG; Solomon, H; Thompson, DD | 1 |
| Grasser, W; Rodan, GA; Rosenblatt, M; Seedor, JG; Thompson, DD | 1 |
7 review(s) available for alendronate and Disease Models, Animal
| Article | Year |
|---|---|
[Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence].
Topics: Aged; Alendronate; Animals; Bone Density; Disease Models, Animal; Drug Combinations; Drug Interactions; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Hydroxycholecalciferols; Long-Term Care; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Rats; Risedronic Acid | 2012 |
Enhancement of bone consolidation in mandibular distraction osteogenesis: a contemporary review of experimental studies involving adjuvant therapies.
Topics: Adjuvants, Pharmaceutic; Alendronate; Animals; Bone Morphogenetic Protein 4; Bone Regeneration; Disease Models, Animal; Dogs; Electric Stimulation Therapy; Erythropoietin; Genetic Therapy; Mandible; Nerve Growth Factor; Osteogenesis; Osteogenesis, Distraction; Rabbits; Rats; Risk Assessment; Stem Cell Transplantation; Treatment Outcome | 2013 |
[Research progress of protective effects of alendronate on articular cartilage in osteoarthritis].
Topics: Alendronate; Animals; Anterior Cruciate Ligament; Bone Density Conservation Agents; Bone Remodeling; Cartilage, Articular; Collagen; Cytokines; Disease Models, Animal; Humans; Knee Joint; Matrix Metalloproteinase 13; Osteoarthritis; Rabbits | 2012 |
[Bisphosphonate treatment in osteonecrosis of the femoral head].
Topics: Alendronate; Animals; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Femur Head Necrosis; Humans; Rats | 2007 |
[Assessment of bone quality. Effects of osteoporosis medications on structural and mechanical integrity of bone].
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Humans; Imaging, Three-Dimensional; Osteoporosis; Teriparatide; Tomography, X-Ray Computed | 2008 |
Preclinical pharmacology of alendronate.
Topics: Alendronate; Animals; Calcification, Physiologic; Diphosphonates; Disease Models, Animal; Estrogens; Etidronic Acid; Female; Hyperparathyroidism; Microscopy, Electron; Osteoclasts; Osteoporosis; Ovariectomy; Papio; Rats | 1993 |
Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications.
Topics: Absorptiometry, Photon; Alendronate; Animals; Bone and Bones; Bone Density; Bone Remodeling; Calcification, Physiologic; Disease Models, Animal; Female; Humans; Osteoporosis, Postmenopausal; Papio | 1997 |
1 trial(s) available for alendronate and Disease Models, Animal
| Article | Year |
|---|---|
Prevention of disuse osteoporosis in rats by Cordyceps sinensis extract.
Topics: Alendronate; Animals; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Cordyceps; Disease Models, Animal; Drugs, Chinese Herbal; Female; Hindlimb Suspension; Lumbar Vertebrae; Male; Osteoporosis; Phytotherapy; Rats; Rats, Sprague-Dawley; Treatment Outcome; X-Ray Microtomography | 2012 |
173 other study(ies) available for alendronate and Disease Models, Animal
| Article | Year |
|---|---|
Infrared Spectroscopy-Determined Bone Compositional Changes Associated with Anti-Resorptive Treatment of the
Topics: Alendronate; Animals; Bone and Bones; Disease Models, Animal; Mice; Minerals; Osteogenesis Imperfecta; Water | 2022 |
Anti-osteoporosis Effect of Fisetin against Ovariectomy Induced Osteoporosis in Rats: In silico, in vitro and in vivo Activity.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Antioxidants; Bone Density; Cell Line; Cell Proliferation; Cytokines; Disease Models, Animal; Female; Flavonols; Humans; Osteoporosis, Postmenopausal; Osteoprotegerin; Ovariectomy; Phytotherapy; RANK Ligand; Rats, Sprague-Dawley; Receptors, Calcitriol; Receptors, Estrogen | 2022 |
Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.
Topics: Alendronate; Animals; Bone Resorption; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred C57BL; Osteoclasts; Osteogenesis; Osteolysis; Osteoporosis, Postmenopausal; RANK Ligand | 2022 |
How does alendronate affect orthodontic tooth movement in osteogenesis imperfecta: an in vivo study on a mice model.
Topics: Alendronate; Animals; Bone Remodeling; Collagen; Disease Models, Animal; Female; Male; Mice; Osteoclasts; Osteogenesis; Osteogenesis Imperfecta; Periodontal Ligament; Tartrate-Resistant Acid Phosphatase; Tooth Movement Techniques | 2023 |
Axial Compressive Loading Attenuates Early Osteoarthritis by Reducing Subchondral Bone Remodeling.
Topics: Alendronate; Animals; Bone Remodeling; Cartilage, Articular; Disease Models, Animal; Inflammation; Mice; Osteoarthritis; Osteophyte; X-Ray Microtomography | 2023 |
Changes in the Subchondral Bone, Visfatin, and Cartilage Biomarkers after Pharmacological Treatment of Experimental Osteoarthritis with Metformin and Alendronate.
Topics: Alendronate; Animals; Biomarkers; Cartilage, Articular; Disease Models, Animal; Metformin; Mice; Nicotinamide Phosphoribosyltransferase; Osteoarthritis | 2023 |
Effect of intra-articular injection of a hyaluronic acid-alendronate conjugate on post-traumatic osteoarthritis induced by destabilization of the medial meniscus in rats.
Topics: Alendronate; Animals; Cartilage, Articular; Disease Models, Animal; Hyaluronic Acid; Injections, Intra-Articular; Menisci, Tibial; Osteoarthritis; Rats; Rats, Sprague-Dawley; Sodium Chloride; Vascular Endothelial Growth Factor A; X-Ray Microtomography | 2023 |
Icariin reduces bone loss in a Rankl-induced transgenic medaka (Oryzias latipes) model for osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Disease Models, Animal; Etidronic Acid; Fish Diseases; Flavonoids; Organisms, Genetically Modified; Oryzias; Osteoporosis; RANK Ligand | 2021 |
Specific inhibition of FAK signaling attenuates subchondral bone deterioration and articular cartilage degeneration during osteoarthritis pathogenesis.
Topics: Alendronate; Animals; Anterior Cruciate Ligament; Bone and Bones; Bone Remodeling; Cartilage, Articular; Chondrocytes; Disease Models, Animal; Endothelial Cells; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Male; Osteoarthritis; Rats, Sprague-Dawley | 2020 |
Preliminary study on the electromagnetic field treatment of osteoporosis in rats.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Female; Magnetic Field Therapy; Osteoporosis; Rats; Rats, Sprague-Dawley | 2020 |
Ultrasound-assisted transdermal delivery of alendronate for the treatment of osteoporosis.
Topics: Administration, Cutaneous; Alendronate; Animals; Biological Availability; Bone Density Conservation Agents; Calcium; Chitosan; Disease Models, Animal; Drug Delivery Systems; Drug Liberation; Male; Nanoparticles; Osteoporosis; Particle Size; Permeability; Rats; Rats, Sprague-Dawley; Skin; Transdermal Patch; Treatment Outcome; Ultrasonic Waves | 2020 |
Phosphatidylserine nanoliposomes inhibit glucocorticoid-induced osteoporosis: A potential combination therapy with alendronate.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Femur; Liposomes; Male; Methylprednisolone; Osteocalcin; Osteoclasts; Osteoporosis; Phosphatidylserines; Rats; Rats, Wistar | 2020 |
Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors.
Topics: Alendronate; Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Disease Models, Animal; Doxorubicin; Drug Synergism; Female; Heparin, Low-Molecular-Weight; Liposomes; Mice; Nanoparticles; Osteosarcoma; RAW 264.7 Cells; Xenograft Model Antitumor Assays | 2020 |
Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Female; Femur; Fracture Healing; Mice; Osteogenesis; Osteogenesis Imperfecta; Thiophenes | 2021 |
Sustained release of ancillary amounts of testosterone and alendronate from PLGA coated pericard membranes and implants to improve bone healing.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Regeneration; Coated Materials, Biocompatible; Delayed-Action Preparations; Disease Models, Animal; Femur; Humans; Male; Osseointegration; Polylactic Acid-Polyglycolic Acid Copolymer; Prostheses and Implants; Rabbits; Rats; Testosterone; Titanium | 2021 |
Investigating the Preventive Effects of 99Tc-Methylenediphosphonate on a Glucocorticoid-Induced Osteoporosis Rabbit Model.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Calcium Carbonate; Diphosphonates; Disease Models, Animal; Female; Glucocorticoids; Osteoporosis; Rabbits; Technetium | 2021 |
Raloxifene but not alendronate can compensate the impaired osseointegration in osteoporotic rats.
Topics: Alendronate; Animals; Bone Density; Dental Implants; Disease Models, Animal; Female; Immunoenzyme Techniques; Implants, Experimental; Microscopy, Confocal; Osseointegration; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Tibia; X-Ray Microtomography | 2018 |
Effects of alendronate on osteoporosis treatment and levels of related cytokines.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Cytokines; Disease Models, Animal; Dyskinesias; Female; Fibroblast Growth Factor 2; Humans; Insulin-Like Growth Factor I; Osteoporosis; Ovariectomy; Rabbits; Treatment Outcome; Up-Regulation | 2017 |
Evaluation of the Effects of Photobiomodulation on Biomechanical Properties and Hounsfield Unit of Partial Osteotomy Healing in an Experimental Rat Model of Type I Diabetes and Osteoporosis.
Topics: Alendronate; Animals; Biomechanical Phenomena; Blood Glucose; Diabetes Mellitus, Type 1; Disease Models, Animal; Female; Low-Level Light Therapy; Osteoporosis; Osteotomy; Ovariectomy; Random Allocation; Rats; Rats, Wistar; Reference Values; Stress, Mechanical; Tibia; Wound Healing | 2017 |
Diagnostic PET Imaging of Mammary Microcalcifications Using
Topics: Alendronate; Animals; Calcinosis; Cell Line, Tumor; Copper Radioisotopes; Disease Models, Animal; Female; Heterocyclic Compounds, 1-Ring; Mammary Neoplasms, Experimental; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2017 |
Desalted Duck Egg White Peptides Promote Calcium Uptake and Modulate Bone Formation in the Retinoic Acid-Induced Bone Loss Rat and Caco-2 Cell Model.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Caco-2 Cells; Calcium; Calcium Channels; Disease Models, Animal; Ducks; Egg White; Female; Humans; Osteocalcin; Osteoclasts; Osteogenesis; Peptides; Rats; Rats, Wistar; Tretinoin; TRPV Cation Channels | 2017 |
Inhibition of mevalonate pathway prevents ischemia-induced cardiac dysfunction in rats via RhoA-independent signaling pathway.
Topics: Alendronate; Animals; Calcium Signaling; Calcium-Binding Proteins; Cardiomyopathy, Dilated; Cell Line; Disease Models, Animal; Geranyltranstransferase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mevalonic Acid; Myocardial Infarction; Myocytes, Cardiac; Rats, Sprague-Dawley; rho GTP-Binding Proteins; Rosuvastatin Calcium; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Tacrolimus Binding Proteins; Ventricular Function, Left; Ventricular Remodeling | 2017 |
Impairment of cold injury-induced muscle regeneration in mice receiving a combination of bone fracture and alendronate treatment.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Cold Injury; Disease Models, Animal; Fractures, Bone; Male; Mice, Inbred ICR; Muscle, Skeletal; Regeneration | 2017 |
High Bone Turnover in Mice Carrying a Pathogenic Notch2 Mutation Causing Hajdu-Cheney Syndrome.
Topics: Adult; Alendronate; Animals; Base Sequence; Bone Diseases, Metabolic; Bone Marrow Cells; Bone Remodeling; Bone Resorption; Cancellous Bone; Cytokines; Disease Models, Animal; Hajdu-Cheney Syndrome; Humans; Male; Mice; Mutation; Organ Size; Osteogenesis; Porosity; Receptor, Notch2; Skull | 2018 |
Promotion effect of extracts from plastrum testudinis on alendronate against glucocorticoid-induced osteoporosis in rat spine.
Topics: Alendronate; Animals; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Core Binding Factor Alpha 1 Subunit; Dexamethasone; Disease Models, Animal; Drug Synergism; Glucocorticoids; Immunohistochemistry; Osteoclasts; Osteoporosis; Rats; Spine; Tissue Extracts; X-Ray Microtomography | 2017 |
Role of subchondral bone properties and changes in development of load-induced osteoarthritis in mice.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Cancellous Bone; Cartilage, Articular; Disease Models, Animal; Epiphyses; Male; Mice; Mice, Inbred C57BL; Osteoarthritis, Knee; Osteophyte; Tibia; Weight-Bearing; X-Ray Microtomography | 2017 |
Effects of local alendronate administration on bone defect healing. Histomorphometric and radiological evaluation in a rabbit model.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Regeneration; Disease Models, Animal; Female; Fracture Healing; Fractures, Bone; Male; Rabbits | 2017 |
Synergistic effect of photodynamic therapy and alendronate on alveolar bone loss in rats with ligature-induced periodontitis.
Topics: Alendronate; Alveolar Bone Loss; Animals; Bone Density; Disease Models, Animal; Drug Combinations; Drug Synergism; Gingiva; Ligation; Male; Mandible; Periodontitis; Photochemotherapy; Random Allocation; Rats; Rats, Wistar | 2018 |
Novel and rapid osteoporosis model established in zebrafish using high iron stress.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Calcification, Physiologic; Disease Models, Animal; Iron; Iron Overload; Osteoblasts; Osteogenesis; Osteoporosis; Zebrafish | 2018 |
Healing of fractures in osteoporotic bones in mice treated with bisphosphonates - A transcriptome analysis.
Topics: Alendronate; Animals; Biomarkers; Bone Resorption; Cluster Analysis; Diphosphonates; Disease Models, Animal; Femur; Fracture Healing; Gene Expression Profiling; Gene Ontology; Mice, Inbred C57BL; Osteoclasts; Osteoporotic Fractures; Ovariectomy; Spine; X-Ray Microtomography | 2018 |
In silico estrogen-like activity and in vivo osteoclastogenesis inhibitory effect of Cicer arietinum extract.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Calcium-Binding Proteins; Cicer; Disease Models, Animal; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Regulation; Genistein; Humans; Isoflavones; Membrane Glycoproteins; Molecular Docking Simulation; Osteogenesis; Osteoporosis; Osteoprotegerin; Ovariectomy; Phytoestrogens; Phytotherapy; Protein Structure, Secondary; RANK Ligand; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Peptide | 2018 |
Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model.
Topics: Alendronate; Animals; Biomarkers; Bone Density; Bone Remodeling; Collagen Type I; Diabetes Mellitus, Experimental; Diphosphonates; Disease Models, Animal; Female; Humans; Lumbar Vertebrae; Osteocalcin; Osteoporosis, Postmenopausal; Ovariectomy; Peptides; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Streptozocin; X-Ray Microtomography | 2018 |
Effects of strontium ranelate on wear particle‑induced aseptic loosening in female ovariectomized mice.
Topics: Aged; Alendronate; Animals; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Female; Humans; Mice; Osteocalcin; Osteoclasts; Osteogenesis; Osteolysis; Osteoporosis; Osteoprotegerin; Prosthesis Failure; Thiophenes | 2018 |
Bone-targeted delivery of TGF-β type 1 receptor inhibitor rescues uncoupled bone remodeling in Camurati-Engelmann disease.
Topics: Alendronate; Animals; Bone Remodeling; Camurati-Engelmann Syndrome; Cells, Cultured; Disease Models, Animal; Drug Delivery Systems; Drug Design; HeLa Cells; Humans; Male; Mice; Mice, Mutant Strains; Mice, Transgenic; Osteogenesis; Receptor, Transforming Growth Factor-beta Type I; Transforming Growth Factor beta1 | 2018 |
Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Bortezomib; Breast Neoplasms; Catechols; Cell Line; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Female; Hemolysis; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Prodrugs; Proteasome Inhibitors; RAW 264.7 Cells | 2018 |
The effects of bisphosphonate on pain-related behavior and immunohistochemical analyses in hindlimb-unloaded mice.
Topics: Alendronate; Animals; Behavior, Animal; Bone Density Conservation Agents; Disease Models, Animal; Hindlimb Suspension; Male; Mice; Osteoporosis; Pain | 2018 |
Interleukin-6 Inhibitor Suppresses Hyperalgesia Without Improvement in Osteoporosis in a Mouse Pain Model of Osteoporosis.
Topics: Alendronate; Animals; Antibodies; Behavior, Animal; Bone Density Conservation Agents; Combined Modality Therapy; Disease Models, Animal; Female; Hyperalgesia; Interleukin-6; Male; Mice; Osteoporosis; Ovariectomy; Pain; Treatment Outcome | 2019 |
Raman spectroscopy as a predictive tool for monitoring osteoporosis therapy in a rat model of postmenopausal osteoporosis.
Topics: Alendronate; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Estrogens; Female; Humans; Keratins; Osteoporosis, Postmenopausal; Parathyroid Hormone; Rats; Rats, Sprague-Dawley; Spectrum Analysis, Raman; X-Ray Microtomography | 2019 |
A novel hybrid compound LLP2A-alendronate accelerates open fracture healing in a rabbit model.
Topics: Alendronate; Animals; Dipeptides; Disease Models, Animal; Female; Fracture Healing; Male; Neovascularization, Pathologic; Osteogenesis; Phenylurea Compounds; Rabbits | 2019 |
Protective effects of alendronate in Triton X-100-induced hyperlipidemia in rats.
Topics: Alanine Transaminase; Alendronate; Animals; Aspartate Aminotransferases; Cholesterol, HDL; Cholesterol, LDL; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperlipidemias; Hypolipidemic Agents; Octoxynol; Protective Agents; Rats; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances; Triglycerides | 2019 |
Clinical pathologies of bone fracture modelled in zebrafish.
Topics: Alendronate; Animal Fins; Animals; Bony Callus; Diphosphonates; Disease Models, Animal; Fracture Healing; Fractures, Bone; Fractures, Ununited; Osteoclasts; Osteogenesis Imperfecta; Staphylococcus aureus; Zebrafish | 2019 |
Long-term effects of alendronate on fracture healing and bone remodeling of femoral shaft in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Remodeling; Disease Models, Animal; Drug Administration Schedule; Female; Femoral Fractures; Femur; Fracture Healing; Ovariectomy; Rats; Rats, Sprague-Dawley; Time Factors | 2013 |
Prevention of osteonecrosis of the jaw by mucoperiosteal coverage in a rat model.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Dexamethasone; Disease Models, Animal; Epithelium; Gingivectomy; Glucocorticoids; Injections, Subcutaneous; Male; Maxilla; Molar; Mouth Mucosa; Periosteum; Random Allocation; Rats; Rats, Sprague-Dawley; Surgical Flaps; Time Factors; Tooth Extraction; Tooth Socket; Wound Healing | 2013 |
Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Compressive Strength; Disease Models, Animal; Disease Progression; Female; Immunohistochemistry; Intervertebral Disc Degeneration; Lumbar Vertebrae; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; X-Ray Microtomography | 2013 |
Core decompression and alendronate treatment of the osteonecrotic rat femoral head: computer-assisted analysis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Combined Modality Therapy; Decompression, Surgical; Disease Models, Animal; Female; Femur Head; Femur Head Necrosis; Image Processing, Computer-Assisted; Osteonecrosis; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2013 |
Diabetes mellitus and corticotherapy as risk factors for alendronate-related osteonecrosis of the jaws: a study in Wistar rats.
Topics: Adrenal Cortex Hormones; Alendronate; Animals; Biopsy, Needle; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diabetes Mellitus, Experimental; Disease Models, Animal; Immunohistochemistry; Random Allocation; Rats; Rats, Wistar; Reference Values; Risk Factors | 2014 |
Quercetin prevents experimental glucocorticoid-induced osteoporosis: a comparative study with alendronate.
Topics: Alendronate; Animals; Biomarkers; Body Mass Index; Bone Density Conservation Agents; Disease Models, Animal; Female; Femur; Glucocorticoids; Methylprednisolone Hemisuccinate; Osteogenesis; Osteoporosis; Pilot Projects; Quercetin; Random Allocation; Rats; Rats, Sprague-Dawley | 2013 |
Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bony Callus; Densitometry; Disease Models, Animal; Female; Fracture Healing; Genotype; Male; Mice; Mice, Mutant Strains; Osteogenesis Imperfecta; Spectrum Analysis, Raman; X-Ray Microtomography | 2013 |
Methionine down-regulates TLR4/MyD88/NF-κB signalling in osteoclast precursors to reduce bone loss during osteoporosis.
Topics: Acid Phosphatase; Administration, Oral; Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Cells, Cultured; Chemokine CCL3; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Female; Inflammation Mediators; Isoenzymes; Methionine; Myeloid Differentiation Factor 88; NF-kappa B; Osteoclasts; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; RNA Interference; Signal Transduction; Tartrate-Resistant Acid Phosphatase; Time Factors; Toll-Like Receptor 4 | 2014 |
Synergistic antiosteoporotic effect of Lepidium sativum and alendronate in glucocorticoid-induced osteoporosis in Wistar rats.
Topics: Alendronate; Animals; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Calcium; Disease Models, Animal; Drug Synergism; Female; Femur; Glucocorticoids; Lepidium sativum; Osteoporosis; Phosphoric Monoester Hydrolases; Phosphorus; Phytotherapy; Plant Extracts; Rats; Rats, Wistar; Tibia | 2013 |
Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcitriol; Calcium, Dietary; Disease Models, Animal; Genotype; Hypercalciuria; Intestinal Absorption; Intestinal Mucosa; Kidney; Kidney Calculi; Male; Phenotype; Rats; Rats, Sprague-Dawley; Time Factors | 2014 |
Inhibitory effect of bisphosphonate on osteoclast function contributes to improved skeletal pain in ovariectomized mice.
Topics: Acid Phosphatase; Alendronate; Animals; Diphosphonates; Disease Models, Animal; Female; Isoenzymes; Mice; Mice, Inbred C57BL; Osteoclasts; Osteoporosis; Ovariectomy; Pain; Pain Threshold; Posterior Horn Cells; Proto-Oncogene Proteins c-fos; Tartrate-Resistant Acid Phosphatase; Transient Receptor Potential Channels | 2015 |
Influence of alendronate administration regimen on the final outcome of implant osseointegration in an osteoporotic model.
Topics: Alendronate; Animals; Bone Cements; Bone Density Conservation Agents; Calcium Phosphates; Dexamethasone; Disease Models, Animal; Female; Femur; Implants, Experimental; Osseointegration; Osteoporosis; Prospective Studies; Rabbits | 2014 |
Effects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone mass.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Femur; Hormone Replacement Therapy; Lumbar Vertebrae; Osteoporosis; Osteoporotic Fractures; Ovariectomy; Parathyroid Hormone; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Stress, Mechanical; Weight-Bearing; X-Ray Microtomography | 2014 |
Technical advance: liposomal alendronate depletes monocytes and macrophages in the nonhuman primate model of human disease.
Topics: Alendronate; Animals; Bone Marrow; Cell Count; Cell Movement; Cell Separation; Disease Models, Animal; DNA Replication; Drug Evaluation, Preclinical; Flow Cytometry; Humans; Injections, Intraperitoneal; Injections, Intravenous; Liposomes; Macaca mulatta; Macrophages; Monocytes; Myeloid Cells | 2014 |
Adaptive growth factor delivery from a polyelectrolyte coating promotes synergistic bone tissue repair and reconstruction.
Topics: Alendronate; Angiogenesis Inducing Agents; Animals; Becaplermin; Biocompatible Materials; Bone and Bones; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Regeneration; Disease Models, Animal; Lactic Acid; Male; Membranes, Artificial; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Proto-Oncogene Proteins c-sis; Rats; Rats, Sprague-Dawley; Regenerative Medicine; Skull; Wound Healing | 2014 |
An NMR metabolomic study on the effect of alendronate in ovariectomized mice.
Topics: Alendronate; Animals; Bone Density; Disease Models, Animal; Female; Glucose; Humans; Inactivation, Metabolic; Magnetic Resonance Imaging; Metabolomics; Mice; Osteoblasts; Osteoclasts; Osteoporosis; Ovariectomy | 2014 |
Alterations in collagen and mineral nanostructure observed in osteoporosis and pharmaceutical treatments using simultaneous small- and wide-angle X-ray scattering.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Collagen; Disease Models, Animal; Female; Humans; Minerals; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; Scattering, Small Angle; Sodium Fluoride; X-Ray Diffraction | 2014 |
The standardized BHH10 extract, a combination of Astragalus membranaceus, Cinnamomum cassia, and Phellodendron amurense, reverses bone mass and metabolism in a rat model of postmenopausal osteoporosis.
Topics: Alendronate; Animals; Astragalus propinquus; Body Weight; Bone Density; Bone Resorption; Cinnamomum aromaticum; Disease Models, Animal; Estradiol; Female; Femur; Organ Size; Osteocalcin; Osteogenesis; Osteoporosis; Ovariectomy; Phellodendron; Plant Extracts; Rats; Rats, Sprague-Dawley; Toxicity Tests, Acute; Toxicity Tests, Chronic | 2015 |
Preventive effects of withaferin A isolated from the leaves of an Indian medicinal plant Withania somnifera (L.): comparisons with 17-β-estradiol and alendronate.
Topics: Acid Phosphatase; Alendronate; Animals; Biomarkers; Bone and Bones; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Estradiol; Female; Isoenzymes; Mice; Mice, Inbred BALB C; Osteocalcin; Osteoclasts; Osteoporosis; Ovariectomy; Plant Leaves; Plants, Medicinal; Receptor Activator of Nuclear Factor-kappa B; Tartrate-Resistant Acid Phosphatase; Tumor Necrosis Factor-alpha; Withania; Withanolides | 2015 |
Preparation of an injectable depot system for long-term delivery of alendronate and evaluation of its anti-osteoporotic effect in an ovariectomized rat model.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; Disease Models, Animal; Drug Delivery Systems; Emulsions; Female; Hyaluronic Acid; Injections, Intramuscular; Lactic Acid; Male; Microspheres; Osteoporosis; Ovariectomy; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rabbits; Rats; Rats, Sprague-Dawley | 2015 |
Alendronate rescued osteoporotic phenotype in a model of glucocorticoid-induced osteoporosis in adult zebrafish scale.
Topics: Acid Phosphatase; Alendronate; Alkaline Phosphatase; Animals; Biomarkers; Bone Density Conservation Agents; Bone Matrix; Bone Remodeling; Disease Models, Animal; Glucocorticoids; Isoenzymes; Male; Osteoclasts; Osteoporosis; Phenotype; Prednisolone; Tartrate-Resistant Acid Phosphatase; Time Factors; Tissue Culture Techniques; Zebrafish; Zebrafish Proteins | 2015 |
Perioperative alendronate, risedronate, calcitonin and indomethacin treatment alters femoral stem fixation and periprosthetic bone mineral density in ovariectomized rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Calcitonin; Disease Models, Animal; Drug Therapy, Combination; Female; Follow-Up Studies; Indomethacin; Osteoporosis; Ovariectomy; Postoperative Care; Postoperative Complications; Preoperative Care; Rats; Rats, Wistar; Risedronic Acid | 2015 |
Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collagen; Disease Models, Animal; Female; Femur; Fractures, Bone; Male; Mice; Osteogenesis Imperfecta; Recombinant Fusion Proteins; Sex Factors; Spectroscopy, Fourier Transform Infrared; Time Factors | 2015 |
In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Female; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Ovariectomy; Rats, Sprague-Dawley; Receptors, Prostaglandin E, EP4 Subtype; Structure-Activity Relationship; Weight-Bearing; X-Ray Microtomography | 2016 |
An osteonecrosis model induced by oral bisphosphonate in ovariectomised rats.
Topics: Administration, Oral; Alendronate; Animals; Bone Density Conservation Agents; Disease Models, Animal; Female; Injections; Lipopolysaccharides; Mandible; Osteonecrosis; Ovariectomy; Rats; Rats, Wistar | 2015 |
Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer.
Topics: Alendronate; Animals; Antibiotics, Antineoplastic; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Doxorubicin; Drug Liberation; Female; Humans; Hydrogen-Ion Concentration; Kinetics; Mice; Micelles; Molecular Targeted Therapy; Nuclear Magnetic Resonance, Biomolecular; Particle Size; Polyethylene Glycols; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2015 |
The determination of apoptosis rates on articular cartilages of ovariectomized rats with and without alendronate treatment.
Topics: Alendronate; Animals; Apoptosis; Bone Density Conservation Agents; Cartilage, Articular; Disease Models, Animal; Female; Immunohistochemistry; In Situ Nick-End Labeling; Osteoarthritis; Osteoporosis; Ovariectomy; Random Allocation; Rats; Rats, Wistar | 2016 |
Metabolite Profiling Reveals the Effect of Dietary Rubus coreanus Vinegar on Ovariectomy-Induced Osteoporosis in a Rat Model.
Topics: Acetic Acid; Alendronate; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gas Chromatography-Mass Spectrometry; Humans; Metabolome; Osteoporosis, Postmenopausal; Ovariectomy; Plant Extracts; Rats; Rubus | 2016 |
Experimental osteonecrosis: development of a model in rodents administered alendronate.
Topics: Alendronate; Alkaline Phosphatase; Animals; Biomarkers; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Collagen Type I; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Male; Peptides; Rats, Sprague-Dawley; Time Factors; Tooth Extraction; Tooth Socket | 2016 |
Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Remodeling; Disease Models, Animal; Drug Evaluation, Preclinical; Femur; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lumbar Vertebrae; Male; Nephrectomy; Osteoporosis; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Teriparatide; X-Ray Microtomography | 2017 |
Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment.
Topics: Alendronate; Alkaline Phosphatase; Anastrozole; Animals; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Disease Models, Animal; Drugs, Chinese Herbal; Female; Mice, Inbred BALB C; Nitriles; Osteoporosis; Ovariectomy; Triazoles | 2017 |
Alendronate inhibits hyperalgesia and suppresses neuropeptide markers of pain in a mouse model of osteoporosis.
Topics: Alendronate; Animals; Biomarkers; Bone Density Conservation Agents; Calcitonin Gene-Related Peptide; Disease Models, Animal; Female; Hyperalgesia; Mice; Osteoporosis; Ovariectomy; Pain; TRPV Cation Channels | 2017 |
Local action of sodium alendronate in bone repair of spontaneously hypertensive rat (SHR).
Topics: Alendronate; Analysis of Variance; Animals; Bone Density Conservation Agents; Bone Regeneration; Disease Models, Animal; Female; Femoral Fractures; Femur; Hypertension; Male; Rats; Rats, Inbred SHR; Time Factors | 2008 |
Effect of low-power gallium-aluminum-arsenium laser therapy (830 nm) in combination with bisphosphonate treatment on osteopenic bone structure: an experimental animal study.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Diseases, Metabolic; Combined Modality Therapy; Disease Models, Animal; Female; Lasers, Semiconductor; Low-Level Light Therapy; Ovariectomy; Rats; Rats, Wistar; Spine | 2009 |
Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Estradiol; Female; Genistein; Osteoporosis; Ovariectomy; Phytoestrogens; Raloxifene Hydrochloride; Random Allocation; Rats; Rats, Sprague-Dawley; Time Factors | 2008 |
The effects of alendronate in the treatment of experimental osteonecrosis of the hip in adult rabbits.
Topics: Acetabulum; Adult; Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Cone-Beam Computed Tomography; Disease Models, Animal; Femur Head Necrosis; Humans; Male; Microradiography; Rabbits; Random Allocation | 2009 |
Peritoneal macrophage depletion by liposomal bisphosphonate attenuates endometriosis in the rat model.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Chemokine CCL2; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Endometriosis; Female; Flow Cytometry; Immunohistochemistry; Injections, Intraperitoneal; Liposomes; Macrophages, Peritoneal; Rats; Rats, Inbred Strains; Tumor Necrosis Factor-alpha | 2009 |
Medical treatment of otosclerosis: rationale for use of bisphosphonates.
Topics: Aged; Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Death; Combined Modality Therapy; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ear, Inner; Ear, Middle; Etidronic Acid; Follow-Up Studies; Hearing Aids; Hearing Loss, Sensorineural; Humans; Male; Middle Aged; Osteoclasts; Osteoprotegerin; Otosclerosis; Risedronic Acid; Speech Discrimination Tests; Speech Reception Threshold Test; Stapes Surgery; Tinnitus | 2008 |
Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage.
Topics: Alendronate; Animals; Computer Simulation; Disease Models, Animal; Dogs; Etidronic Acid; Fractures, Bone; Risedronic Acid; Spine; Substrate Specificity | 2009 |
Biocompatibility evaluation of alendronate paste in rat's subcutaneous tissue.
Topics: Alendronate; Animals; Biocompatible Materials; Disease Models, Animal; Injections, Subcutaneous; Male; Materials Testing; Ointments; Rats; Rats, Wistar; Root Canal Irrigants; Root Resorption; Subcutaneous Tissue; Tooth Avulsion; Tooth Replantation; Tooth Socket | 2009 |
Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate.
Topics: Alendronate; Alkaline Phosphatase; Animals; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcification, Physiologic; Collagen Type I; Disease Models, Animal; Female; Femoral Fractures; Femur; Genistein; Injections, Subcutaneous; Methylprednisolone; Osteoporosis; Peptides; Rats; Rats, Sprague-Dawley; Time Factors | 2009 |
Alendronate treatment improves bone-pedicle screw interface fixation in posterior lateral spine fusion: an experimental study in a porcine model.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Bone Screws; Bone Transplantation; Disease Models, Animal; Equipment Failure Analysis; Female; Graft Survival; Lumbar Vertebrae; Osseointegration; Spinal Fusion; Swine | 2010 |
Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Resorption; Diphosphonates; Disease Models, Animal; Humans; Hyperparathyroidism; Imidazoles; Immunohistochemistry; Male; Mice; Mice, Transgenic; Osteoclasts; Osteoprotegerin; Porosity; Primary Myelofibrosis; Receptor, Parathyroid Hormone, Type 1; Tomography, X-Ray Computed; Zoledronic Acid | 2009 |
Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Female; Femoral Fractures; Femur; Osteoporosis; Risk Factors | 2009 |
Experimental results of combining bisphosphonates with allograft in a rat model.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Bone Transplantation; Diphosphonates; Disease Models, Animal; Female; Graft Rejection; Rats; Rats, Sprague-Dawley; Transplantation, Homologous | 2009 |
Mandibular necrosis in beagle dogs treated with bisphosphonates.
Topics: Alendronate; Alveolar Process; Animals; Bone Density Conservation Agents; Bone Matrix; Bone Remodeling; Cell Death; Cell Survival; Coloring Agents; Diphosphonates; Disease Models, Animal; Dogs; Female; Haversian System; Imidazoles; L-Lactate Dehydrogenase; Mandibular Diseases; Osteocytes; Osteonecrosis; Ribs; Rosaniline Dyes; Time Factors; Zoledronic Acid | 2009 |
Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis?
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Plates; Bone Regeneration; Bony Callus; Disease Models, Animal; Estrogens; Female; Fracture Fixation; Fractures, Bone; Osteoporosis; Osteotomy; Rats; Rats, Sprague-Dawley; Recovery of Function; Tibia; Treatment Outcome; Wound Healing | 2010 |
[Skeletal biomechanical effectiveness of retinoic acid on induction of osteoporotic rats treated by alendronate and qianggu capsules].
Topics: Alendronate; Animals; Biomechanical Phenomena; Disease Models, Animal; Drugs, Chinese Herbal; Female; Fracture Healing; Fractures, Bone; Osteoporosis; Phytotherapy; Rats; Rats, Sprague-Dawley; Tretinoin | 2009 |
Vibrational bone characteristics versus bone density for the assessment of osteoporosis in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density; Disease Models, Animal; Female; Fourier Analysis; Linear Models; Osteoporosis; Ovariectomy; Ovary; Rats; Rats, Wistar; Reproducibility of Results; Sensitivity and Specificity; Statistics, Nonparametric; Tibia; Vibration | 2010 |
Comparison of the effects of alendronate sodium and calcitonin on bone-prosthesis osseointegration in osteoporotic rats.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Calcitonin; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Joint Prosthesis; Osseointegration; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Treatment Outcome | 2011 |
Comment on Xue et al.: Alendronate treatment improves bone-pedicle screw interface fixation in posterior lateral spine fusion: an experimental study in a porcine model.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Remodeling; Bone Screws; Disease Models, Animal; Equipment Failure Analysis; Fractures, Stress; Humans; Osseointegration; Osteogenesis; Spinal Fusion | 2010 |
Effective dosage and administration schedule of oral alendronate for non-nociceptive symptoms in rats with chronic constriction injury.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Complex Regional Pain Syndromes; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Male; Rats; Rats, Sprague-Dawley; Sciatic Nerve; Temperature | 2010 |
In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat.
Topics: Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Disease Models, Animal; Drug Therapy, Combination; Epiphyses; Etidronic Acid; Female; Femur; Magnetic Resonance Imaging; Meloxicam; Osteoarthritis, Knee; Osteophyte; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stifle; Thiazines; Thiazoles; Tibia; Tomography, X-Ray Computed; Water | 2010 |
Effect of alendronate on alveolar bone resorption and angiogenesis in rats with experimental periapical lesions.
Topics: Acid Phosphatase; Alendronate; Alveolar Bone Loss; Alveolar Process; Animals; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Drug Administration Schedule; Isoenzymes; Male; Mandible; Microvessels; Neovascularization, Physiologic; Periapical Diseases; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Tartrate-Resistant Acid Phosphatase | 2010 |
Osteogenic activity of locally applied small molecule drugs in a rat femur defect model.
Topics: Alendronate; Animals; Bone Density; Disease Models, Animal; Femur; Lovastatin; Male; Omeprazole; Organ Size; Osteogenesis; Rats; Rats, Sprague-Dawley; Wound Healing; X-Ray Microtomography | 2010 |
[Comparison of effects of Wujia Bugu decoction) and alendronate sodium on protection the bone loss of hindlimb unloaded rats].
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Disease Models, Animal; Drugs, Chinese Herbal; Femur; Hindlimb Suspension; Humans; Humerus; Male; Random Allocation; Rats; Rats, Wistar | 2010 |
Evaluation of a novel osteoporotic drug delivery system in vitro: alendronate-loaded calcium phosphate cement.
Topics: Alendronate; Animals; Bone Cements; Bone Density Conservation Agents; Calcium Phosphates; Cell Proliferation; Disease Models, Animal; Drug Delivery Systems; Materials Testing; Mesenchymal Stem Cells; Microscopy, Electron, Scanning; Osteoporosis; Rats; Spectroscopy, Fourier Transform Infrared | 2010 |
Route of administration-dependent anti-inflammatory effect of liposomal alendronate.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Carotid Stenosis; Chemistry, Pharmaceutical; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Compounding; Endometriosis; Female; Injections, Intraperitoneal; Injections, Intravenous; Liposomes; Macrophages, Peritoneal; Monocytes; Rabbits; Rats; Tissue Distribution | 2010 |
Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Drug Therapy, Combination; Imidazoles; Jaw; Osteonecrosis; Random Allocation; Rats; Rats, Wistar; Tooth Extraction; Zoledronic Acid | 2011 |
Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome.
Topics: Alendronate; Animals; Aorta; Aortic Aneurysm; Bone Diseases, Metabolic; Bone Morphogenetic Proteins; Bone Resorption; Disease Models, Animal; Fibrillin-1; Fibrillins; Losartan; Marfan Syndrome; Mice; Mice, Inbred C57BL; Microfilament Proteins; Mutation; Osteoblasts; Osteoclasts; Osteogenesis; Spine; Tomography, X-Ray Computed; Transforming Growth Factor beta | 2010 |
The effect of oestrogen and alendronate therapies on postmenopausal bone loss around osseointegrated titanium implants.
Topics: Absorptiometry, Photon; Alendronate; Amino Acids; Animals; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Dental Implants; Dental Materials; Disease Models, Animal; Estradiol; Estrogen Replacement Therapy; Female; Femur; Lumbar Vertebrae; Osseointegration; Osteocalcin; Osteoclasts; Osteogenesis; Osteoporosis; Ovariectomy; Random Allocation; Rats; Rats, Wistar; Tibia; Titanium | 2011 |
The influence of alendronate on spine fusion in an osteoporotic animal model.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Bone Transplantation; Combined Modality Therapy; Disease Models, Animal; Female; Humans; Injections, Subcutaneous; Lumbar Vertebrae; Osteogenesis; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Spinal Fusion; Time Factors; Tomography, X-Ray Computed | 2011 |
Enhancement of subchondral bone quality by alendronate administration for the reduction of cartilage degeneration in the early phase of experimental osteoarthritis.
Topics: Absorptiometry, Photon; Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Cartilage; Collagen Type II; Disease Models, Animal; Histocytochemistry; Immunohistochemistry; Male; Matrix Metalloproteinase 13; Microscopy; Osteoarthritis; Rabbits | 2011 |
Synthesis and in vivo bioactivity of lipophilic alendronate derivatives against osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Chromatography, High Pressure Liquid; Disease Models, Animal; Hindlimb Suspension; Male; Osteoporosis; Rats; Rats, Sprague-Dawley; Solubility | 2011 |
Efficacy of serotonin inhibition in mouse models of bone loss.
Topics: Aging; Alendronate; Animals; Bone and Bones; Bone Resorption; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gastrointestinal Tract; Low Density Lipoprotein Receptor-Related Protein-5; Mice; Mice, Inbred C57BL; Organ Size; Osteoporosis; Ovariectomy; Phenotype; Pyrimidines; Serotonin; Time Factors; Treatment Outcome; Tryptophan Hydroxylase | 2011 |
Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
Topics: Acid Phosphatase; Alendronate; Animals; Antibodies, Monoclonal; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Morphogenetic Proteins; Disease Models, Animal; Female; Genetic Markers; Isoenzymes; Osteocalcin; Osteogenesis; Ovariectomy; Rats; Rats, Sprague-Dawley; Tartrate-Resistant Acid Phosphatase | 2011 |
Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.
Topics: Acid Phosphatase; Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Isoenzymes; Male; Mice; Osteogenesis Imperfecta; Osteoporotic Fractures; RANK Ligand; Recombinant Fusion Proteins; Tartrate-Resistant Acid Phosphatase; Weight Gain; X-Ray Microtomography | 2012 |
Antiosteoporotic activity of Davallia formosana.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Catechin; Cell Differentiation; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Femur; Mice; Osteoclasts; Osteoporosis; Ovariectomy; Plant Extracts; Plants, Medicinal; Polypodiaceae; RANK Ligand; Rats; Rats, Wistar; Rhizome; Solvents; Time Factors; X-Ray Microtomography | 2012 |
Bisphosphonate-induced osteonecrosis of the jaw in a rat model arises first after the bone has become exposed. No primary necrosis in unexposed bone.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cell Death; Cell Survival; Dexamethasone; Disease Models, Animal; Gingival Diseases; Gingivectomy; Glucocorticoids; L-Lactate Dehydrogenase; Male; Maxilla; Molar; Oral Ulcer; Osteocytes; Random Allocation; Rats; Rats, Sprague-Dawley; Tooth Extraction; Tooth Socket; Wound Healing | 2012 |
Pharmacodynamic responses to combined treatment regimens with the calcium sensing receptor antagonist JTT-305/MK-5442 and alendronate in osteopenic ovariectomized rats.
Topics: Alendronate; Animals; Benzoates; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Estrogens; Female; Ovariectomy; Parathyroid Hormone; Propanolamines; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing | 2012 |
Development of a novel self-dissolving microneedle array of alendronate, a nitrogen-containing bisphosphonate: evaluation of transdermal absorption, safety, and pharmacological effects after application in rats.
Topics: Administration, Cutaneous; Alendronate; Animals; Biological Availability; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Disease Models, Animal; Dosage Forms; Drug Delivery Systems; Female; Growth Plate; Hyaluronic Acid; Male; Miniaturization; Needles; Osteoporosis; Ovariectomy; Permeability; Rats; Rats, Sprague-Dawley; Rats, Wistar; Skin; Skin Absorption; Solubility; Technology, Pharmaceutical | 2012 |
Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis.
Topics: Alendronate; Animals; Anterior Cruciate Ligament Injuries; Benzamides; Biomarkers; Bone Density Conservation Agents; Cartilage, Articular; Cathepsin K; Collagen Type I; Cysteine Proteinase Inhibitors; Disease Models, Animal; Disease Progression; Female; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Osteoarthritis; Peptide Fragments; Peptides; Rabbits; Thiazoles | 2012 |
Downregulation of the inflammatory response by CORM-3 results in protective effects in a model of postmenopausal arthritis.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Arthritis; Biomarkers; Disease Models, Animal; Down-Regulation; Female; Humans; Inflammation; Mice; Mice, Inbred DBA; Organometallic Compounds; Osteoporosis, Postmenopausal | 2012 |
Peri-implant and systemic effects of high-/low-affinity bisphosphonate-hydroxyapatite composite coatings in a rabbit model with peri-implant high bone turnover.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Coated Materials, Biocompatible; Disease Models, Animal; Durapatite; Male; Materials Testing; Osseointegration; Osteogenesis; Prostheses and Implants; Prosthesis Design; Prosthesis Implantation; Rabbits; Tibia | 2012 |
Alendronate enhances osseous healing in a rat calvarial defect model.
Topics: Alendronate; Analysis of Variance; Animals; Bone Density Conservation Agents; Bone Transplantation; Disease Models, Animal; Male; Osteoblasts; Osteoclasts; Osteogenesis; Rats; Rats, Wistar; Skull; Wound Healing | 2012 |
Heparanase role in the treatment of avascular necrosis of femur head.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Combined Modality Therapy; Decompression, Surgical; Disease Models, Animal; Female; Femur Head; Femur Head Necrosis; Glucuronidase; Hemostasis; Immunohistochemistry; Injections, Subcutaneous; Lipoproteins; Orthopedic Procedures; Rats; Rats, Sprague-Dawley; Staining and Labeling; Thromboplastin; Time Factors | 2013 |
Unfocused extracorporeal shock waves induce anabolic effects in osteoporotic rats.
Topics: Alendronate; Anabolic Agents; Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Combined Modality Therapy; Disease Models, Animal; Female; High-Energy Shock Waves; Osteogenesis; Osteoporosis; Ovariectomy; Rats; Rats, Wistar; Tibia; X-Ray Microtomography | 2013 |
Experimental development of bisphosphonate-related osteonecrosis of the jaws in rodents.
Topics: Alendronate; Alkaline Phosphatase; Animals; Biomarkers; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Remodeling; Collagen Type I; Disease Models, Animal; Jaw; Male; Molar; Orthognathic Surgical Procedures; Peptides; Rats; Time Factors; Tooth Extraction; Weight Gain | 2013 |
Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Collagen Type I; Disease Models, Animal; Drug Evaluation, Preclinical; Elasticity; Female; Fractures, Spontaneous; Humans; Male; Mice; Mice, Mutant Strains; Osteogenesis Imperfecta | 2002 |
Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Calcification, Physiologic; Disease Models, Animal; Mice; Mice, Mutant Strains; Osteogenesis; Osteogenesis Imperfecta; Spectroscopy, Fourier Transform Infrared | 2003 |
The influence of alendronate on bone formation and resorption in a rat ectopic bone development model.
Topics: Alendronate; Analysis of Variance; Animals; Bone Density; Bone Diseases, Metabolic; Bone Marrow; Bone Resorption; Dermatologic Surgical Procedures; Disease Models, Animal; Image Processing, Computer-Assisted; Injections, Intravenous; Male; Microradiography; Ossification, Heterotopic; Osteoblasts; Osteogenesis; Random Allocation; Rats; Rats, Inbred Strains; Statistics as Topic; Time Factors | 2003 |
Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta.
Topics: Alendronate; Animals; Bone Development; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Genotype; Growth Plate; Humerus; Male; Mice; Mice, Mutant Strains; Osteogenesis Imperfecta; Ulna | 2003 |
A rat model for testing pharmacologic treatments of pressure-related bone loss.
Topics: Alendronate; Animals; Antirheumatic Agents; Bone Plates; Bone Resorption; Disease Models, Animal; Drug Administration Schedule; Etanercept; Immunoglobulin G; Osteogenesis; Parathyroid Hormone; Pressure; Prosthesis Implantation; Rats; Rats, Sprague-Dawley; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha | 2003 |
A histopathological investigation on the effect of systemic administration of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the rat mandible.
Topics: Alendronate; Alveolar Bone Loss; Alveolar Process; Animals; Bone Resorption; Chi-Square Distribution; Collagen; Disease Models, Animal; Fibrosis; Injections, Subcutaneous; Male; Mandible; Mandibular Diseases; Osteoblasts; Osteoclasts; Periodontium; Rats; Surgical Flaps | 2003 |
Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits.
Topics: Alendronate; Animals; Cell Count; Cell Division; Cell Movement; Diet, Atherogenic; Disease Models, Animal; Graft Occlusion, Vascular; Hyperplasia; Iliac Artery; Immunity, Innate; Leukocyte Count; Liposomes; Macrophages; Monocytes; Muscle, Smooth, Vascular; Rabbits; Stents; Tunica Intima | 2003 |
Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening.
Topics: Administration, Topical; Alendronate; Animals; Disease Models, Animal; Male; Movement; Osteolysis; Pressure; Prosthesis Failure; Rats; Rats, Sprague-Dawley; Tibia | 2004 |
The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model.
Topics: Acid Phosphatase; Alendronate; Animals; Anterior Cruciate Ligament; Bone Remodeling; Calcinosis; Cartilage, Articular; Collagen; Collagen Type I; Collagen Type II; Disease Models, Animal; Disease Progression; Extracellular Matrix Proteins; Glycoproteins; Isoenzymes; Male; Matrilin Proteins; Osteoarthritis, Knee; Osteoclasts; Peptides; Rats; Sclerosis; Severity of Illness Index; Tartrate-Resistant Acid Phosphatase; Transforming Growth Factor beta | 2004 |
Effects of D-003, a mixture of high molecular weight aliphatic acids from sugar cane wax, on bones from ovariectomized rats.
Topics: Administration, Oral; Alendronate; Animals; Bone Density; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Acids; Female; Femur; Lumbar Vertebrae; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley | 2004 |
Healing properties of allograft from alendronate-treated animal in lumbar spine interbody cage fusion.
Topics: Alendronate; Analysis of Variance; Animals; Biopsy, Needle; Bone Transplantation; Disease Models, Animal; Female; Immunohistochemistry; Lumbar Vertebrae; Random Allocation; Sensitivity and Specificity; Spinal Fusion; Statistics, Nonparametric; Swine; Tomography, X-Ray Computed; Transplantation, Autologous; Transplantation, Homologous | 2005 |
High-dose alendronate uncouples osteoclast and osteoblast function: a study in a rat spine pseudarthrosis model.
Topics: Alendronate; Analysis of Variance; Animals; Chi-Square Distribution; Disease Models, Animal; Dose-Response Relationship, Drug; Lumbar Vertebrae; Male; Osteoblasts; Osteoclasts; Pseudarthrosis; Rats; Rats, Sprague-Dawley; Wound Healing | 2004 |
Alendronate inhibits bone resorption at the bone-screw interface.
Topics: Acid Phosphatase; Alendronate; Animals; Bone Resorption; Bone Screws; Cathepsin K; Cathepsins; Disease Models, Animal; External Fixators; Femur; Isoenzymes; Male; Prosthesis Failure; Rats; Rats, Wistar; Tartrate-Resistant Acid Phosphatase | 2005 |
Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Disease Models, Animal; Fractures, Bone; Mice; Osteogenesis Imperfecta | 2005 |
Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice.
Topics: Alendronate; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Carotid Stenosis; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Etidronic Acid; Female; Mice; Mice, Inbred C57BL; Mice, Knockout; Risedronic Acid; Treatment Outcome | 2005 |
Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model.
Topics: Absorptiometry, Photon; Alendronate; Analysis of Variance; Animals; Bone and Bones; Bone Density; Calcium; Disease Models, Animal; Fallopia japonica; Female; Femur; Osteoporosis; Ovariectomy; Random Allocation; Rats; Rats, Wistar; Resveratrol; Stilbenes; Weight Gain | 2005 |
The influence of alendronate treatment and bone graft volume on posterior lateral spine fusion in a porcine model.
Topics: Administration, Oral; Alendronate; Animals; Bone Density Conservation Agents; Bone Transplantation; Disease Models, Animal; Female; Graft Survival; Lumbar Vertebrae; Osseointegration; Osteogenesis; Spinal Fusion; Swine | 2005 |
Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.
Topics: Alendronate; Animals; Apoptosis; Arthritis, Experimental; bcl-X Protein; Bone Marrow Cells; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Immunoenzyme Techniques; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Transgenic; Osteoclasts; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-ets; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors; Tumor Necrosis Factor-alpha; Up-Regulation | 2005 |
Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone Morphogenetic Proteins; Bone Resorption; Cattle; Chondrogenesis; Disease Models, Animal; Drug Synergism; Female; Glycoproteins; Injections, Subcutaneous; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Ossification, Heterotopic; Osteoblasts; Osteoclasts; Osteogenesis; Osteoporosis; Osteoprotegerin; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor | 2005 |
Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture.
Topics: Absorptiometry, Photon; Aging; Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Calcium; Callithrix; Disease Models, Animal; Female; Humans; Male; Osteogenesis; Osteoporosis; Phosphorus | 2007 |
Alendronate enhances antibiotic-impregnated bone grafts in the treatment of osteomyelitis.
Topics: Alendronate; Animals; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Transplantation; Disease Models, Animal; Drug Carriers; Drug Therapy, Combination; Osteomyelitis; Rats; Rats, Wistar; Vancomycin; Wound Healing | 2008 |
Alendronate therapy in cyclosporine-induced alveolar bone loss in rats.
Topics: Acid Phosphatase; Alendronate; Alkaline Phosphatase; Alveolar Bone Loss; Alveolar Process; Animals; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcium; Cell Count; Cyclosporine; Disease Models, Animal; Immunosuppressive Agents; Isoenzymes; Male; Osteoblasts; Osteocalcin; Osteoclasts; Random Allocation; Rats; Rats, Wistar; Tartrate-Resistant Acid Phosphatase | 2007 |
Antiangiogenic effects of bisphosphonates on laser-induced choroidal neovascularization in mice.
Topics: Alendronate; Angiogenesis Inhibitors; Animals; Cell Culture Techniques; Choroid; Choroidal Neovascularization; Clodronic Acid; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Fluorescein Angiography; Injections, Intraperitoneal; Integrin alphaV; Integrin beta1; Integrin beta3; Laser Coagulation; Male; Mice; Mice, Inbred C57BL; Pigment Epithelium of Eye; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A | 2007 |
The effects of bone remodeling inhibition by alendronate on three-dimensional microarchitecture of subchondral bone tissues in guinea pig primary osteoarthrosis.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Cartilage, Articular; Collagen; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Guinea Pigs; Joints; Knee Joint; Male; Osteoarthritis; Stress, Mechanical; Tibia; Weight-Bearing | 2008 |
Effect of preoperative combined treatment with alendronate and calcitriol on fixation of hydroxyapatite-coated implants in ovariectomized rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Calcitriol; Coated Materials, Biocompatible; Disease Models, Animal; Drug Combinations; Durapatite; Female; Femur; Osteoporosis; Ovariectomy; Preoperative Care; Prostheses and Implants; Rats; Rats, Wistar | 2008 |
Beneficial effects of combined administration of alendronate and alfacalcidol on cancellous bone mass of the tibia in orchidectomized rats: a bone histomorphometry study.
Topics: Alendronate; Animals; Body Weight; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Disease Models, Animal; Drug Therapy, Combination; Hydroxycholecalciferols; Male; Orchiectomy; Random Allocation; Rats; Rats, Sprague-Dawley; Tibia | 2008 |
Natural isoprenoids are able to reduce inflammation in a mouse model of mevalonate kinase deficiency.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Acyclic Monoterpenes; Alendronate; Animals; Disease Models, Animal; Diterpenes; Farnesol; Inflammation; Male; Mevalonate Kinase Deficiency; Mice; Mice, Inbred BALB C; Terpenes | 2008 |
Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT.
Topics: Alendronate; Animals; Biocompatible Materials; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Image Processing, Computer-Assisted; Imidazoles; Mice; Osteoclasts; Osteolysis; Osteoprotegerin; Polyethylene; Prosthesis Failure; Skull; Surface Properties; Tomography, X-Ray Computed; Zoledronic Acid | 2008 |
Effect of ovariectomy and alendronate on implant osseointegration in rat maxillary bone.
Topics: Alendronate; Analysis of Variance; Animals; Bone Density; Bone Density Conservation Agents; Dental Implantation, Endosseous; Dental Implants; Disease Models, Animal; Estrogens; Female; Injections, Subcutaneous; Maxilla; Osseointegration; Ovariectomy; Ovary; Rats; Rats, Sprague-Dawley | 2008 |
Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
Topics: Alendronate; Animals; Autoradiography; Bone and Bones; Bone Resorption; Calcium; Carbon Radioisotopes; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Etidronic Acid; Hydroxycholecalciferols; Hypercalcemia; Male; Organ Culture Techniques; Osteoclasts; Pamidronate; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley; Tibia; Tissue Distribution | 1995 |
Alendronate treatment of naturally-occurring periodontitis in beagle dogs.
Topics: Alendronate; Alveolar Bone Loss; Analysis of Variance; Animals; Diphosphonates; Disease Models, Animal; Dogs; Double-Blind Method; Drug Evaluation, Preclinical; Female; Periodontitis | 1995 |
The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats.
Topics: Alendronate; Animals; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Diphosphonates; Disease Models, Animal; Hyperthyroidism; Male; Osteoclasts; Rats; Rats, Sprague-Dawley; Thyroxine; Tibia | 1993 |
Effect of bisphosphonates on the increase in bone resorption induced by a low calcium diet.
Topics: Alendronate; Animals; Bone Resorption; Calcium; Calcium, Dietary; Clodronic Acid; Diphosphonates; Disease Models, Animal; Homeostasis; Ibandronic Acid; Male; Rats; Rats, Wistar; Tetracycline | 1996 |
Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Topics: Alendronate; Amino Acids; Animals; Biomarkers; Body Weight; Bone Resorption; Cholesterol; Disease Models, Animal; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Organ Size; Osteoporosis, Postmenopausal; Ovariectomy; Piperidines; Radioimmunoassay; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tamoxifen; Uterus | 1996 |
Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice.
Topics: Alendronate; Animals; Antibodies, Monoclonal; Antigens; Bone Marrow; Bone Marrow Cells; Bone Resorption; Calcium; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression; Injections, Subcutaneous; Macrophages; Metatarsal Bones; Mice; Monocytes; Organ Culture Techniques; Osteoclasts; Radiography; Stem Cells; Tibia | 1997 |
Alendronate prevents cyclosporin A-induced osteopenia in the rat.
Topics: Administration, Oral; Alendronate; Analysis of Variance; Animals; Body Weight; Bone Diseases, Metabolic; Bone Resorption; Calcitriol; Calcium; Cyclosporine; Disease Models, Animal; Image Processing, Computer-Assisted; Immunosuppressive Agents; Injections, Subcutaneous; Male; Osteocalcin; Osteoclasts; Parathyroid Hormone; Random Allocation; Rats; Rats, Sprague-Dawley; Tibia | 1997 |
Alendronate: preclinical studies.
Topics: Alendronate; Animals; Bone Density; Bone Remodeling; Bone Resorption; Disease Models, Animal; Female; Osteoporosis; Papio | 1997 |
Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats.
Topics: Alendronate; Animals; Bone Resorption; Calcium; Calcium Oxalate; Calcium Phosphates; Calcium, Dietary; Creatinine; Disease Models, Animal; Female; Humans; Kidney Calculi; Magnesium; Male; Phosphorus; Quaternary Ammonium Compounds; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley | 1999 |
Alendronate did not inhibit instability-induced bone resorption. A study in rats.
Topics: Alendronate; Animals; Bone Plates; Bone Resorption; Disease Models, Animal; Drug Evaluation, Preclinical; Joint Prosthesis; Male; Prosthesis Failure; Rats; Rats, Sprague-Dawley; Titanium | 1999 |
Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats.
Topics: Administration, Buccal; Administration, Oral; Administration, Topical; Alendronate; Alveolar Bone Loss; Animals; Chi-Square Distribution; Disease Models, Animal; Dose-Response Relationship, Drug; Follow-Up Studies; Gelatin Sponge, Absorbable; Image Processing, Computer-Assisted; Intraoperative Care; Mandible; Microradiography; Multivariate Analysis; Periodontium; Rats; Rats, Wistar; Surgical Flaps | 2000 |
The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model.
Topics: Administration, Topical; Alendronate; Alveolar Bone Loss; Alveolar Process; Animals; Chi-Square Distribution; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Etidronic Acid; Heterocyclic Compounds; Microradiography; Multivariate Analysis; Rats; Rats, Wistar | 2000 |
Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis.
Topics: Alendronate; Animals; Arthritis; Arthroplasty; Cell Division; Disease Models, Animal; Female; Male; Mice; Mice, Inbred CBA; Osteoclasts; Osteolysis; Pentoxifylline; Postoperative Complications; Prostheses and Implants; Skull; Stress, Mechanical; Tumor Necrosis Factor-alpha | 2000 |
Effect of 17beta-estradiol or alendronate on the bone densitometry, bone histomorphometry and bone metabolism of ovariectomized rats.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Densitometry; Disease Models, Animal; Estradiol; Female; Femur; Osteoporosis; Ovariectomy; Rats; Rats, Wistar | 2001 |
Effect of topical alendronate on root resorption of dried replanted dog teeth.
Topics: Administration, Topical; Alendronate; Animals; Ankylosis; Bicuspid; Chi-Square Distribution; Dental Cementum; Desiccation; Disease Models, Animal; Dogs; Isotonic Solutions; Osteoclasts; Root Canal Therapy; Root Resorption; Statistics as Topic; Time Factors; Tissue Preservation; Tooth Avulsion; Tooth Replantation; Tooth Root; Wound Healing | 2001 |
A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta.
Topics: Alendronate; Animals; Bone and Bones; Bone Development; Collagen; Disease Models, Animal; Fractures, Bone; Mice; Mice, Mutant Strains; Osteogenesis Imperfecta | 2001 |
The effect of alendronate (Fosamax) and implant surface on bone integration and remodeling in a canine model.
Topics: Alendronate; Animals; Arthroplasty, Replacement, Hip; Bone Plates; Bone Remodeling; Disease Models, Animal; Dogs; Female; Femur; Humans; Implants, Experimental; Microscopy, Electron, Scanning; Osseointegration; Osteolysis; Osteoporosis, Postmenopausal; Ovariectomy; Prosthesis Failure; Stress, Mechanical; Surface Properties | 2001 |
Sintered dicalcium pyrophosphate increases bone mass in ovariectomized rats.
Topics: Administration, Oral; Alendronate; Alkaline Phosphatase; Animals; Bone Density; Calcium Pyrophosphate; Disease Models, Animal; Female; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Wistar | 2002 |
Inhibition of particulate debris-induced osteolysis by alendronate in a rat model.
Topics: Alendronate; Animals; Disease Models, Animal; Male; Osteolysis; Polymethyl Methacrylate; Prostheses and Implants; Random Allocation; Rats; Rats, Sprague-Dawley | 2002 |
[The treatment of osteoporosis and bone resorption of alveoli with alendronate in rat model].
Topics: Alendronate; Alveolar Process; Animals; Bone Density; Bone Resorption; Calcium; Disease Models, Animal; Female; Osteoporosis; Rats; Rats, Sprague-Dawley | 2001 |
Effects of alendronate on particle-induced osteolysis in a rat model.
Topics: Alendronate; Animals; Bone and Bones; Bone Resorption; Disease Models, Animal; Injections, Intra-Articular; Male; Osteolysis; Polyethylene; Prostheses and Implants; Rats; Rats, Sprague-Dawley | 2002 |
Reduction of instability-induced bone resorption using bisphosphonates: high doses are needed in rats.
Topics: Alendronate; Animals; Bone Plates; Bone Resorption; Clodronic Acid; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Immunohistochemistry; Joint Instability; Male; Osseointegration; Preoperative Care; Probability; Prostheses and Implants; Rats; Rats, Wistar; Reference Values; Sensitivity and Specificity; Statistics, Nonparametric; Tibia | 2002 |
Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment.
Topics: Alendronate; alpha-Fetoproteins; Animals; Bone and Bones; Bone Remodeling; Bone Resorption; Calcitonin; Calcium; Calcium-Binding Proteins; Disease Models, Animal; Etidronic Acid; Extracellular Matrix Proteins; Feeding Behavior; Glycoproteins; Humans; Injections; Male; Matrix Gla Protein; Osteoprotegerin; Phosphates; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Time Factors | 2002 |
The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons.
Topics: Acid Phosphatase; Alendronate; Analysis of Variance; Animals; Bone and Bones; Bone Density; Calcium; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Estradiol; Female; Humans; Osteocalcin; Osteoporosis, Postmenopausal; Ovariectomy; Papio; Parathyroid Hormone; Radioimmunoassay | 1992 |
Effect of alendronate (bisphosphonate) in animal models of hyperparathyroidism.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Calcium; Diphosphonates; Disease Models, Animal; Hyperparathyroidism, Secondary; Male; Osteoclasts; Parathyroid Hormone; Rats; Rats, Inbred Strains | 1991 |